FDA approves the first oral drug for reducing multiple sclerosis relapses.
D000284:Administration, Oral; D002490:Central Nervous System / Q000187:drug effects*; D017277:Drug Approval; D000068876:Fingolimod Hydrochloride; D006801:Humans; D018836:Inflammation Mediators / Q000627:therapeutic use*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D011409:Propylene Glycols / Q000627:therapeutic use*; D055502:Secondary Prevention; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D018836:Inflammation Mediators; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine